515. Powles, T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature, 2014. 515: 558. 516. Rosenberg, J.E., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single- arm, multicentre, phase 2 trial. Lancet, 2016. 387: 1909. 517. Bellmunt, J., et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med, 2017. 376: 1015. 518. Sharma, P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol, 2017. 18: 312.
75 MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER - LIMITED UPDATE MARCH 2018 519. Farina, M.S., et al. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives. Drugs, 2017. 77: 1077. 520. Apolo, A.B., et al. Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. J Clin Oncol, 2017. 35: 2117. 521. Powles, T., et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol, 2017. 3: e172411. 522. Youssef, R.F., et al. Molecular targets and targeted therapies in bladder cancer management. World J Urol, 2009. 27: 9. 523. Shariat, S.F., et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol, 2010. 183: 1744. 524. Song, S., et al. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A, 2000. 97: 8658. 525. Gomez-Roman, J.J., et al. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res, 2005. 11: 459. 526. Ioachim, E., et al. Thrombospondin-1 expression in urothelial carcinoma: prognostic significance and association with p53 alterations, tumour angiogenesis and extracellular matrix components. BMC Cancer, 2006. 6: 140. 527. Gallagher, D.J., et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol, 2009. 20: 305. 528. Flaig, T.W., et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology, 2011. 78: 863. 529. Hoffmann, A.C., et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia, 2010. 12: 628.
You've reached the end of your free preview.
Want to read all 78 pages?
- Fall '18
- The American, bladder cancer